U.S. markets open in 4 hours 34 minutes
  • S&P Futures

    3,855.25
    +7.00 (+0.18%)
     
  • Dow Futures

    31,072.00
    +59.00 (+0.19%)
     
  • Nasdaq Futures

    11,917.50
    +37.25 (+0.31%)
     
  • Russell 2000 Futures

    1,732.90
    +4.30 (+0.25%)
     
  • Crude Oil

    98.30
    -0.23 (-0.23%)
     
  • Gold

    1,739.80
    +3.30 (+0.19%)
     
  • Silver

    19.23
    +0.07 (+0.34%)
     
  • EUR/USD

    1.0195
    +0.0010 (+0.10%)
     
  • 10-Yr Bond

    2.9130
    0.0000 (0.00%)
     
  • Vix

    26.63
    -0.91 (-3.30%)
     
  • GBP/USD

    1.1958
    +0.0036 (+0.30%)
     
  • USD/JPY

    136.1340
    +0.2190 (+0.16%)
     
  • BTC-USD

    20,499.70
    +323.49 (+1.60%)
     
  • CMC Crypto 200

    446.19
    +10.66 (+2.45%)
     
  • FTSE 100

    7,168.72
    +60.95 (+0.86%)
     
  • Nikkei 225

    26,490.53
    +382.88 (+1.47%)
     

Bluebird bio Lays Out Planned Updates Ahead Of J.P. Morgan Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Bluebird bio Inc (NASDAQ: BLUE) announced planned updates to be presented at the 40th Annual J.P. Morgan Healthcare conference, including 2022 program milestones and financial outlook.

  • In 2022, bluebird is focused on the FDA review of two gene therapies – betibeglogene autotemcel (beti-cel) for beta-thalassemia and elivaldogene autotemcel (eli-cel) for cerebral adrenoleukodystrophy (CALD).

  • The Company is prepared to launch both beti-cel and eli-cel for patients in the U.S. in mid-2022 if approved by the FDA.

  • An FDA Advisory Committee to discuss the Biologics License Application (BLA) for beti-cel is anticipated on March 9, 2022.

  • Bluebird bio also expects to complete manufacturing commercial drug product validation lots for its third gene therapy, lovotibeglogene autotemcel (lovo-cel), for sickle cell disease in mid-2022.

  • The Company is evaluating the impact of the ongoing partial clinical hold of lovo-cel on the projected timing of Q1 of 2023 for the submission of the BLA.

  • 2022 Financial Outlook: The Company's preliminary restricted cash, cash equivalents, and marketable securities balance were approximately $442 million as of December 31, 2021.

  • As bluebird bio advances its late-stage pipeline assets to the commercial setting, full-year 2022 cash burn is expected to be less than $400 million.

  • The Company plans to explore the sale of priority review vouchers expected to be issued with the U.S. approvals of BLAs for beti-cel and eli-cel. Approximately $150-200 million in non-dilutive cash inflows could potentially be realized from the sales, which would extend the current cash runway into 2023.

  • The Company is also exploring multiple additional financing opportunities while focusing on further cost efficiencies.

  • Price Action: BLUE shares are up 3.72% at $9.76 during the market session on the last check Tuesday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.